PAAXE
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Pharmaust Limited - Entitlement To Shares In Diashi Mining Limited
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PAAXE
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in PAAXE
N/A
PAAXE investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in PAAXE also invest in...
Want more shares? Try these...
Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm focuses on the development of antibody therapies for the treatment of cancer. The company is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The 3E10 antibody has several unusual biological properties not typically seen in antibodies, such as cancer targeting, blood-brain barrier, cell penetrating and inhibit deoxyribonucleic acid (DNA) damage repair. The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The company also uses the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
📊 Share price
